Search
Pivampicillin
go.drugbank.com/drugs/DB01604ApprovedWithdrawnPivalate ester analog of ampicillin.
Products: PIVACIL KAPSUL 350 MG, 1000 ADET, PIVACIL KAPSUL 350 MG, 500 ADETVarlilumab
go.drugbank.com/drugs/DB11930InvestigationalVarlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
PF-04418948
go.drugbank.com/drugs/DB12024InvestigationalPf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).
Categories: Receptors, Prostaglandin E, EP2 SubtypeAVR118
go.drugbank.com/drugs/DB04979InvestigationalAVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity. This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammato...
YSIL6
go.drugbank.com/drugs/DB05017ExperimentalThe molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
E-2012
go.drugbank.com/drugs/DB05171ExperimentalE-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line.
MDX-1379
go.drugbank.com/drugs/DB05329InvestigationalMDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
MUC1 Dendritic Cell Vaccine
go.drugbank.com/drugs/DB05477InvestigationalDendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells. … The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system
IPH 1101
go.drugbank.com/drugs/DB05754ExperimentalIPH 1101 is the most advanced drug candidate of the γδ T cell platform … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.